Metropolis Healthcare Limited launches new laboratory at Chandigarh

Metropolis Healthcare Limited., a leading diagnostics company in India (in terms of revenue)** with widespread presence in India, launched a new test centre cum laboratory (“Lab”) in Chandigarh, covering an area of 1800 sq. feet across three floors. The Lab will provide a comprehensive test menu includes pathology tests ranging from basic biochemistry and surgical pathology to cytogenetics and high-end molecular diagnostic tests. This Lab at Chandigarh is situated close to the PGI Hospital. The Lab is equipped to serve the people of Chandigarh and hospitals and nursing houses in the vicinity. In addition, Metropolis will offer 20% discount on routine tests and free home collection for a period of three months as an Inaugural Launch Offer.

Commenting at the launch of the Lab, Dr Sushil Kanubhai Shah, Chairman and Executive DirectorMetropolis Healthcare Limited, said, “This new Metropolis laboratory is equipped to deliver quality pathology services to the populace of Chandigarh. We are also actively involved in campaigns focused on creating awareness of particular conditions such as cancer, lifestyle diseases, monsoon diseases, and the importance of periodic testing.”

Adding to it, Dr Vijender Singh, Chief Executive Officer, Metropolis Healthcare Limited, said “This launch in Chandigarh is in line with our plan of expanding our service network in other key cities. Further, our value added services, such as house calls, e-services, and longer operating hours for patient touch points and call centres, and home delivery of test reports, make our services easier to use. We intend to continue to improve our value added services to make them more attractive for our existing as well as prospective patients.”

 Disclaimer: Metropolis Healthcare Limited is proposing subject to applicable statutory or regulatory requirements, receipt of requisite approvals, market conditions and other considerations to undertake an initial public offering of its equity shares and has filed a draft red herring prospectus dated September 27, 2018 (“DRHP”) with the Securities and Exchange Board of India (“SEBI”) on September 28, 2018. The DRHP is available on the website of the SEBI at, BSE Limited at, National Stock Exchange of India Limited at and the websites of Book Running Lead Managers at and Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to same, please refer to the DRHP including the section “Risk Factors” of the DRHP. Potential investors should not rely on the DRHP filed with the SEBI for making any investment decision.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular

To Top